Vial: difference between revisions
Diff·revision 25 → 26·00:08, 30 Sep 2025
Difference between revision 25 and revision 26 of Vial. 8 lines changed; the page grew by 1,722 bytes.
| Revision 25 — 15:50, 2 Sep 2025 TitrationTheo (talk) sentence case in headings per PP:MOS 23,302 bytes +336 | Revision 26 — 00:08, 30 Sep 2025 SPPS_Sorrel (talk) clarify that the cake appearance is an indicator, not a specification 25,024 bytes +1,722 | ||
|---|---|---|---|
| 144 | Other glass defects are more mundane and more common: chips at the sealing land, which prevent sealing; stones and cords, which are inclusions and inhomogeneities weakening the wall; and scratches from handling, which initiate breakage. Inspection for these is a fill-finish activity and is treated at [[Vial filling and stoppering]]. | 144 | Other glass defects are more mundane and more common: chips at the sealing land, which prevent sealing; stones and cords, which are inclusions and inhomogeneities weakening the wall; and scratches from handling, which initiate breakage. Inspection for these is a fill-finish activity and is treated at [[Vial filling and stoppering]]. |
| 145 | 145 | ||
| + | 146 | == Vials in unregulated distribution == | |
| + | 147 | Vials of research peptides are physically ordinary — commonly 2R or 6R tubing vials with butyl closures and flip-off ferrules, sourced from the same suppliers that serve pharmaceutical manufacturers. What differs is the documentation attached to them and the inspection they have undergone. | |
| + | 148 | ||
| + | 149 | Labelling practice varies from a printed label naming compound, nominal mass, lot and storage recommendation, to a hand-written designation, to no label at all. Unlabelled vials are supplied deliberately in some channels, on the reasoning that the label is what makes a parcel identifiable; the consequence is that the material's identity depends entirely on packaging that is discarded, and that a [[certificate of analysis]] cannot be tied to a specific container.{{r|usp1207}} | |
| + | 150 | ||
| + | 151 | Because the vial is unremarkable, it carries almost no evidential weight. A professionally printed label, a coloured flip-off button and a crimped seal are all obtainable independently of any manufacturing capability, so their presence does not distinguish material from a competent supplier from material repackaged elsewhere. The examination indicators that do carry some weight are those that are hard to reproduce consistently: agreement between the lot number on the vial and on the certificate, a crimp with no evidence of recapping, a cake consistent in appearance with the stated mass, and headspace behaviour on first penetration consistent with the vial having been sealed under vacuum.{{r|usp1207,ppvial}} | |
| + | 152 | ||
| 146 | == References == | 153 | == References == |
| 147 | {{reflist}} | 154 | {{reflist}} |
| ⋮ | ⋮ | ||
| 161 | <ref name="fda2011">US Food and Drug Administration. "Advisory to Drug Manufacturers: Formation of Glass Lamellae in Certain Injectable Drugs" (March 2011).</ref> | 168 | <ref name="fda2011">US Food and Drug Administration. "Advisory to Drug Manufacturers: Formation of Glass Lamellae in Certain Injectable Drugs" (March 2011).</ref> |
| 162 | <ref name="kirsch1997">Kirsch LE, Nguyen L, Moeckly CS. "Pharmaceutical container/closure integrity I: mass spectrometry-based helium leak rate detection for rubber-stoppered glass vials." ''PDA Journal of Pharmaceutical Science and Technology'' 51(5):187–194 (1997).</ref> | 169 | <ref name="kirsch1997">Kirsch LE, Nguyen L, Moeckly CS. "Pharmaceutical container/closure integrity I: mass spectrometry-based helium leak rate detection for rubber-stoppered glass vials." ''PDA Journal of Pharmaceutical Science and Technology'' 51(5):187–194 (1997).</ref> |
| + | 170 | <ref name="ppvial">PeptidePedia community container-observation tally, 2026 (photographic, self-reported, no chain of custody; weak evidence — see [[Project:Sourcing_guidelines]]).</ref> | |
| 163 | 171 | ||
| 164 | == Further reading == | 172 | == Further reading == |